MedPath

Clinical relevance of circulating tumor cells, ctDNA and diagnostic leukapheresis in pancreatic ductal adenocarcinoma patients

Recruiting
Conditions
C25
Malignant neoplasm of pancreas
Registration Number
DRKS00023362
Lead Sponsor
niversitätsklinikum Hamburg-Eppendorf
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

consent, PDAC, resectable

Exclusion Criteria

no consent, other than PDAC, not resectable

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The overall aim of the study is to establish liquid biopsy protocols for PDAC patients in order to enable a more detailed molecular characterization of the disease and performance of functional test such as drug testing on the cells in the future.
Secondary Outcome Measures
NameTimeMethod
KRAS Hot spot Mutation analysis, 24months follow up, WGS of single cells, cfDNA quantities, CTC counts, portal vein vs. peripheral vein
© Copyright 2025. All Rights Reserved by MedPath